Janssen Corrects Risperdal "Dear Doctor" Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The action follows an FDA warning letter in April. Janssen's previous letter to doctors had suggested Risperdal was safer than other atypical antipsychotics.
You may also be interested in...
J&J Risperdal "Dear Doctor" Letter Minimizes Diabetes Risk, FDA Ad Division Says
The agency warning letter says J&J inappropriately claimed that Risperdal is safer than other atypical antipsychotics. The company is working with FDA to address the agency's concerns as quickly as possible.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products